Dublin-based digital pathology company Deciphex and Novartis have teamed up to create AI tools aimed at transforming preclinical pathology evaluations in drug discovery and development. The terms and financial details of the partnership have not been disclosed.

The partnership is aimed toward the development of AI algorithms and tools that can effectively detect and measure lesions within tissues across various species. This would help streamline pathology assessment in toxicological and efficacy studies. The companies are also working toward gaining regulatory approval for the AI tools and digitizing Novartis's collection of tissue slides.

Deciphex, based in Ireland, develops digital pathology software solutions. The company leverages AI to enhance the efficiency of pathology services in both clinical and research settings. Its key product, Patholytix Preclinical, optimizes the review process of pathology specimens by accelerating evaluations in drug safety assessments.